Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.51 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.51 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485588 | 1.00 | LMNA (0.61) | LMNASMN1; SMN2HTTPLAUALDH1A1 | |
| Acetic Acid SCHEMBL8324881 | 0.95 | LMNA (0.56) | LMNASMN1; SMN2HTTPLAUALDH1A1 | |
| SCHEMBL8156969 | 0.94 | ALDH1A1 (0.58) | LMNASMN1; SMN2HTTPLAUALDH1A1 | |
| SCHEMBL16258192 | 0.94 | ALDH1A1 (0.58) | LMNASMN1; SMN2HTTPLAUALDH1A1 | |
| SCHEMBL3254019 | 0.87 | LMNA (0.58) | LMNASMN1; SMN2HTTPLAUALDH1A1 | |
| SCHEMBL22580054 | 0.87 | LMNA (0.58) | LMNASMN1; SMN2HTTPLAUALDH1A1 | |
| SCHEMBL21771638 | 0.87 | LMNA (0.62) | LMNASMN1; SMN2HTTPLAUALDH1A1 | |
| SCHEMBL1337448 | 0.87 | LMNA (0.58) | LMNASMN1; SMN2HTTPLAUALDH1A1 | |
| SCHEMBL11783251 | 0.86 | HTT (0.66) | LMNASMN1; SMN2HTTPLAUALDH1A1 | |
| SCHEMBL6741072 | 0.86 | LMNA (0.65) | LMNASMN1; SMN2HTTALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015389-A1 | V1A Receptor Partial Agonist and Method of Use | PHARMALN CORP (US) | 2026-01-15 | — | — | US | claimed |
| US-12410211-B2 | V1A receptor partial agonist and method of use | PHARMAIN CORPORATION (US) | 2025-09-09 | — | — | US | claimed |
| US-20230248800-A1 | V1A Receptor Partial Agonist and Method of Use | PHARMAIN CORPORATION | 2023-08-10 | — | — | US | claimed |
| EP-4182021-A2 | V1A RECEPTOR PARTIAL AGONIST AND METHOD OF USE | Pharmain Corporation (US) | 2023-05-24 | — | — | EP | claimed |
| WO-2022141615-A1 | SYNTHESIS METHOD FOR ATOSIBAN | 湖北健翔生物制药有限公司 | 2022-07-07 | — | — | WO | claimed |
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | OLIPASS CORPORATION (KR) | 2022-05-03 | — | — | US | claimed |
| EP-1934561-B1 | IMPROVED TIME/TEMPERATURE INDICATORS | SUN CHEMICAL CORP (US) | 2018-11-07 | — | — | EP | claimed |
| US-20080269050-A1 | Time/Temperature Indicators | SUN CHEMICAL CORPORATION (US) | 2008-10-30 | — | — | US | claimed |
| WO-2008100727-A2 | HIGH-DOSE GLYCINE AS A TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER AND OBSESSIVE-COMPULSIVE SPECTRUM DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-08-21 | — | — | WO | claimed |
| EP-1934561-A1 | IMPROVED TIME/TEMPERATURE INDICATORS | Sun Chemical Corporation (US) | 2008-06-25 | — | — | EP | claimed |
| WO-2007035365-A1 | IMPROVED TIME/TEMPERATURE INDICATORS | SUN CHEMICAL CORPORATION (US) | 2007-03-29 | — | — | WO | claimed |
| WO-2006091464-A1 | IMPROVED TIME/ TEMPERATURE INDICATORS | SUN CHEMICAL CORPORATION (US) | 2006-08-31 | — | — | WO | claimed |
| WO-2006091465-A1 | TIME/TEMPERATURE INDICATORS, THEIR PREPARATION AND USE | SUN CHEMICAL CORPORATION (US) | 2006-08-31 | — | — | WO | claimed |
| US-12624068-B2 | Exon skipping by peptide nucleic acid derivatives | OLIPASS CORPORATION (KR) | 2026-05-12 | — | — | US | disclosed |
| US-20260015389-A1 | V1A Receptor Partial Agonist and Method of Use | PHARMALN CORP (US) | 2026-01-15 | — | — | US | disclosed |
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-RE29668-E | 4-OXO-1,2-BENZOTHIAZINE-3-CARBOXAMIDE, 1,1-DIOXIDES, ANTIINFLAMMATORY | PFIZER INC. (US) | 1978-06-13 | — | — | US | disclosed |
| US-RE29669-E | CYCLIZATION OF GLYCINEAMIDES | PFIZER, INC. (US) | 1978-06-13 | — | — | US | disclosed |
| US-3971802-A | ANTIINFLAMMATORY | PFIZER INC. (US) | 1976-07-27 | — | — | US | disclosed |
| US-3954786-A | ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015389-A1 | V1A Receptor Partial Agonist and Method of Use | AVPR1A, AVPR1B, AVPR2 | LMNA 816/4885SMN1; SMN2 4607/4885HTT 4714/4885 |
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | HIF1A, HIF1AN, UPF1 | LMNA 858/4885SMN1; SMN2 423/4885HTT 960/4885 |
| US-12624068-B2 | Exon skipping by peptide nucleic acid derivatives | NSUN2, NSUN3, UPF1 | LMNA 144/4885SMN1; SMN2 87/4885HTT 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.